One of the lead authors of the study, Paul Hébert, critical-care physician at the Ottawa Hospital in Ottawa, Canada, said that Trasylol should not be used in high-risk cardiac surgery patients. The bad thing about this whole circumstance is that the study could have been done ten years ago, which would have undoubtedly saved many lives. Also, during this economic slump, the high cost of Trasylol is not helping anyone. It was reported that as of early May, there are 83 Trasylol lawsuits pending.

            The suspension of Trasylol, a drug used in heart surgeries sales that has been proven to be fatal, has caused for much talk. Trasylol lawsuits from the families of those affected by the drug’s side-effects will be filed soon, and a Trasylol class-action lawsuit can not be far off. With fatalities over 22,000, Bayer is going to be struggling to find a way out. The drug was speculated to have problems back in 2006, yet it was still approved by the FDA. The reason for this is that Bayer failed to present their research about the relation of kidney failure & Trasylol to the FDA in their September 2006 meeting. The chairman of that FDA advisory panel, Dr. William Hiatt, said that he would have voted for a Trasylol recall back in 2006 if Bayer had not withheld the data from their study

            Napoli Bern Ripka LLP is an experienced firm in the medical negligence field and can provide you with the right information on how to proceed with your case. If you or a loved one have suffered as a result of Trasylol side effects such as kidney failure, heart attack, or stroke you may be entitled to compensation. We are here to help you questions that you may have regarding Trasylol side effects, a possible Trasylol class action lawsuit, or any other type of Trasylol litigation.

This entry was posted on Wednesday, June 18th, 2008 at 10:25 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.